An investigation from the College of Alberta discovered that weight reduction drugs like Ozempic could trigger each waistlines and coronary heart muscle to cut back in dimension.
The well-known medicine lowered cardiac muscle mass in each lab-grown human coronary heart cells and skinny and overweight mice, in keeping with the research, which was revealed in JACC: Fundamental to Translational Science.
Lack of muscle may result from semaglutide
There are virtually all the time hostile results from drugs. Ozempic, a model identify for semaglutide, is a weight-reduction medicine that successfully aids in weight reduction. Nonetheless, this comes with damaging penalties like gastrointestinal points and nausea.
The lack of skeletal muscle is likely one of the further damaging results that semaglutide could trigger, in keeping with analysis. In response to a November Lancet research, muscle loss accounts for as much as 40% of drug-induced weight reduction.
In comparison with the muscle loss from calorie restriction diet or sarcopenia (muscle loss from growing older), this charge of muscle loss is considerably larger, indicating doable future well being issues like weakened immune system, the next danger of an infection, and poor wound therapeutic.
Researchers finding out muscle loss in experimental mouse fashions discovered that semaglutide induced coronary heart muscle to shrink in animals as nicely, however this didn’t impair coronary heart perform.
Variations in coronary heart mass however not coronary heart perform
Male mice have been fed a high-fat, high-sucrose weight loss plan for a couple of weeks earlier than being switched to a “regular” mouse weight loss plan, which allowed the researchers to duplicate how somebody might reduce energy. This allowed them to make use of a mouse mannequin of weight problems.
After that, they gave mice both a management or semaglutide. After three weeks, the mice who acquired the medicine misplaced about 30% of their physique weight and about 65% of their fats mass.
The mice given semaglutide skilled a notable discount in each the entire weight of their hearts and the mass of their left ventricles, that are the center’s major pumping chambers that provide oxygen-rich blood to the physique. Their cardiac cells’ whole floor space was likewise diminished.
There was no impact on the center’s capability to pump blood, chill out, or fill with blood in between beats, indicating that this temporary remedy time had no impact on coronary heart perform.
In lean mice, semaglutide likewise had detrimental results on skeletal muscle; after the identical 3-week remedy interval, they misplaced 8.2% of their skeletal muscle mass with out appreciably altering their physique weight.
Moreover, they noticed the identical alterations because the overweight mice, together with decreased left ventricular mass and whole coronary heart weight, however no alteration in pumping capability.
Much like the mouse research, experiments carried out on lab-grown human coronary heart cells revealed that the floor space of the cells shrank following a 24-hour semaglutide remedy. Nonetheless, additional research are wanted to find out whether or not the medicine additionally reduces coronary heart mass in individuals.
Reference : Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice
